Authors
Latest:
Dr. Grunberg on Barriers to Effective Supportive CareSteven M. Grunberg, MD, University of Vermont, on Barriers to Providing Effective Supportive Care for Patients with Cancer.
Latest:
Dr. Horwitz Discusses the Results of the ECHELON-2 StudySteven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).
Latest:
Dr. Lipkin on Cancer Prevention Vaccine in Preclinical Model of Lynch SyndromeSteven M. Lipkin, MD, PhD, the Gladys and Roland Harriman Professor of Medicine, professor of medicine in the Division of Gastroenterology and Hepatology, and vice chair for research in the Weill Department of Medicine at Weill Cornell Medicine; and a geneticist at NewYork-Presbyterian/Weill Cornell Medical Center, discusses a study of a cancer prevention vaccine in a preclinical model of Lynch syndrome during the 2019 AACR Annual Meeting
Latest:
Dr. Alberts on Unmet Needs in CRCSteven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).
Latest:
Dr. Rosen on the Emergence of Novel Therapies and Research With IO in Hematologic MalignanciesSteven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.
Latest:
Dr. Treon on Breakthroughs in Waldenström's MacroglobulinemiaSteven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.
Latest:
Chasing the Holy Grail of EHR InteroperabilityCOTA Inc, an independent health care informatics company was founded to build research-grade, real-world data to exponentially improve outcomes and reduce costs—ensuring the right care for the right patient every time.
Latest:
Dr. Goldberg on Financial Toxicities Faced in HematologyStuart L. Goldberg, MD, discusses financial toxicities faced in hematology.
Latest:
Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid TumorsStuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.
Latest:
Dr. Lichtman Discusses Supportive and Palliative CareDr. Stuart Lichtman, from Memorial Sloan-Kettering Cancer Center Commack, Explains the Benefits of Supportive and Palliative Care.
Latest:
Dr. Mukherjee on Radioactive Iodine Treatment of Thyroid Cancer and Risk of MDSSudipto Mukherjee, MD, associate staff, Department of Hematology and Oncology, Cleveland Clinic, discusses a study examining the association between radioactive iodine treatment of thyroid cancer and the risk for developing myelodysplastic syndromes.
Latest:
Dr. Movva on Molecular Profiling in SarcomaSujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.
Latest:
Dr. Nallapareddy on the Use of ctDNA Testing in Colorectal CancerSujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).
Latest:
Autophagy Modulation May Be a Novel Approach to Treatment of Advanced CancersAlthough prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.
Latest:
Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLCSukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.
Latest:
Dr. Nagendran on Family History, BRCA Status, and RiskSukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.
Latest:
Dr. Kambhampati on Interferon and Novel Agents in MPNsSuman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon and emerging novel agents in the treatment of patients with myeloproliferative neoplasms.
Latest:
Series Wrap-up: Novel Therapies for mRCCA panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Latest:
Sentinel Lymph Node Excision Has Value in Endometrial CancerAlthough the therapeutic utility of lymphadenectomy is uncertain, it continues to provide information for staging and helps to guide postoperative adjuvant treatment for patients with endometrial cancer.
Latest:
CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Latest:
Dr. Jagannath on the Safety Profile of Selinexor in Multiple MyelomaSundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.
